Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitriol + calcium carbonate is a fixed-dose combination of two agents used primarily to manage conditions associated with low blood calcium levels. Calcitriol is the active form of vitamin D3, which increases intestinal absorption of calcium and phosphate, reduces parathyroid hormone (PTH) secretion, and helps maintain bone mineralization. Calcium carbonate acts as a supplemental source of elemental calcium, essential for bone health and various physiological functions. The combination is indicated for use in patients with chronic kidney disease (CKD), hypoparathyroidism, pseudohypoparathyroidism, vitamin D–dependent rickets, hypophosphatemic rickets/osteomalacia, and other conditions where both active vitamin D and supplemental calcium are required to correct or prevent hypocalcemia[4][9]. The combined therapy improves biochemical parameters related to bone metabolism and may slow the progression of bone loss in early renal failure[4]. However, it carries risks such as hypercalcemia; therefore monitoring serum and urine calcium levels during therapy is recommended[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitriol + calcium carbonate.